Avid Bioservices Inc (CDMO)

[nuke661]

MM,

I was trying to look past the mean OS number and look at the longer term effects. To be frank, I don't understand the 34 dead and 4 alive label below the overall survival graph and how you and ex are interpreting it. To me, an MOS of 6.1 means that it took 6.1 months for 20th patient to die, and that the graph was generated with 4 patients still alive. I don't understand the statement ex made:

Really, 4 patients alive at that point in time is really a very bad number. Even the placebo arm of Sharp did better on OS.

I at first thought he meant that only 4 were alive at 6.1 months but that makes no sense and so I'm sure I misunderstood him or I am way off base.

I still believe that the Yopp trial's significant plus is that it still has 3 patients alive for longer than anyone in the sharp trial and with having a much, much smaller population to have a random possibility to achieve this. And, it appears that this smaller population was also challenged by its inclusion criteria allowing patients in the trial who were worse off than the inclusion criteria for the PIII sharp trial. Again, I'm not sure about this interpretation and would appreciate it if the knowledgeable medical people would provide an assessment.